<DOC>
	<DOCNO>NCT02223260</DOCNO>
	<brief_summary>The aim study investigate safety tolerability dabigatran etexilate solution child age less 1 year , demonstrate comparable PK/PD relationship old child adult confirm dabigatran etexilate dose algorithm child age less 1 year .</brief_summary>
	<brief_title>Tolerability , PK/PD Safety Dabigatran Etexilate Oral Liquid Formulation Children &lt; 1 Year Age</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Neonates infant age &lt; 12 month Visit 1 Objective diagnosis VTE End plan treatment course anticoagulant therapy per standard care investigator site . Written inform consent provide patient 's parent ( ) ( legal guardian ) accord local regulation Visit 1 . Exclusion criterion : Weight le 3 kg Visit 1 Conditions associate increase risk bleed renal dysfunction hepatic disease Anemia thrombocytopenia screening</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>